C
CRNX

Covestor’s Crinetics Pharmaceuticals CRNX Stock Holding History

Covestor’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$54K Buy
1,452
+1,448
+36,200% +$53.8K 0.03% 744
2026
Q1 		$0 Sell
4
-1
-20% -$45 ﹤0.01% 2329
2025
Q4 		$0 Sell
5
-1,440
-100% -$64.1K ﹤0.01% 2325
2025
Q3 		$60K Buy
1,445
+1,439
+23,983% +$46K 0.03% 829
2025
Q2 		$0 Hold
6
– – ﹤0.01% 2281
2025
Q1 		$0 Buy
6
+2
+50% +$75 ﹤0.01% 2295
2024
Q4 		$0 Hold
4
– – ﹤0.01% 2301
2024
Q3 		$0 Hold
4
– – ﹤0.01% 2288
2024
Q2 		$0 Hold
4
– – ﹤0.01% 2303
2024
Q1 		$0 Sell
4
-2
-33% -$78 ﹤0.01% 2305
2023
Q4 		$0 Hold
6
– – ﹤0.01% 2214
2023
Q3 		$0 Sell
6
-1
-14% -$21 ﹤0.01% 2189
2023
Q2 		$0 Hold
7
– – ﹤0.01% 2199
2023
Q1 		$0 Hold
7
– – ﹤0.01% 2093
2022
Q4 		$0 Sell
7
-1
-13% -$18 ﹤0.01% 2128
2022
Q3 		$0 Sell
8
-1
-11% -$20 ﹤0.01% 2069
2022
Q2 		$0 Sell
9
-3
-25% -$60 ﹤0.01% 1978
2022
Q1 		$0 Buy
+12
New +$243 ﹤0.01% 2154

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Covestor's CRNX Position: Q2 2026 in Review

Covestor increased its Crinetics Pharmaceuticals (CRNX) stake by 36,200% in Q2 2026, buying an estimated $53.8K and bringing the position to 1,452 shares worth $54K. The position accounts for 0.03% of the portfolio, ranked #744.

Covestor first reported a position in CRNX in Q1 2022 and has held it in 18 quarters since. The position peaked at $60K in Q3 2025. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • Covestor held 1,452 shares of Crinetics Pharmaceuticals worth $54K as of Q2 2026.
  • Covestor bought 1,448 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $53.8K.
  • Crinetics Pharmaceuticals made up 0.03% of Covestor's portfolio in Q2 2026, its #744 holding.
  • Covestor first reported a position in Crinetics Pharmaceuticals in Q1 2022 and has held it in 18 quarters since.
  • Covestor's Crinetics Pharmaceuticals position peaked at $60K in Q3 2025.
  • 267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Covestor's 13F filing for Q2 2026, filed 7 Aug 2026.